Company intelligence / Profile preview
Proteon Therapeutics
Waltham, Massachusetts, United Statesproteontherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Phase III trial of PRT-201 (vonapanitase) failed to reach its primary endpoint in December 2016, causing stock price to drop more than 75%[1]
- Therapeutic areas
- CardiovascularNephrology
- Modalities
- Recombinant proteins
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Option agreement with Novartis (announced March 2009)[1]
Beyond the preview
Go deeper on Proteon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proteon Therapeutics.